Ledipasvir D-tartrate is primarily used in the treatment of chronic hepatitis C virus (HCV) infection. It is a key component of combination antiviral therapy, often paired with sofosbuvir, to enhance its effectiveness. This combination targets specific proteins within the virus, inhibiting its replication and reducing the viral load in patients. It is particularly effective against HCV genotype 1, which is one of the most common and challenging strains to treat. The therapy is administered orally, offering a convenient and non-invasive treatment option. Ledipasvir D-tartrate has shown high cure rates, significantly improving patient outcomes and reducing the risk of liver-related complications such as cirrhosis and hepatocellular carcinoma. Its use has revolutionized HCV treatment, providing a highly effective and well-tolerated alternative to older, more complex regimens.